HeartWare bags CircuLite for up to $350M with an eye on bigger market share

CircuLite's Synergy system is roughly the size of a AA battery.--Courtesy of CircuLite

HeartWare ($HTWR) has bought out CircuLite for as much as $350 million, acquiring a cardiac assist device for less-severe patients and broadening its offerings in the heart failure world.

Under the deal, HeartWare shelled out $30 million up front, made up of $18 million in stock and the rest in cash to cover CircuLite's debt. The remaining $320 million is tied to clinical and commercial milestones for CircuLite's Synergy system, a so-called partial-support implant that does for early-stage heart-failure patients what HeartWare's banner device does for those with advanced cases, CEO Doug Godshall said.

"CircuLite has pioneered the partial-assist approach and demonstrated that this technique can significantly enhance the quality of life for this group of patients, which is believed to be a substantially larger population than the end-stage heart failure patients that HeartWare currently treats with our full-support ventricular assist devices," Godshall said in a statement. "... While our HVAD and MVAD systems offer minimally invasive treatment to end-stage heart-failure patients, the Synergy platform offers even less invasive and ultimately interventional options to earlier-stage heart-failure patients."

Synergy, roughly the size and weight of a AA battery, is a micropump inserted through an incision in the chest, reducing the heart's workload. The device secured a CE mark last year, but, after a brief commercial release, CircuLite said it's in the midst of upgrading the implant to address some unspecified issues, planning to relaunch it in a phased rollout.

Meanwhile, HeartWare is still riding high off of last year's FDA approval of its HVAD system, last quarter boosting revenue by 140% to $54.8 million and trimming its net loss by more than half to $11.4 million. The company's shares are up about 30% since its Nov. 7 earnings release, opening at $96.40 on Monday.

- read the statement

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.